James Wallace, MD
Urology · Meridian, MSNPI 1881794162
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,316 of the $3,843 with a category attached, or 86.3%. It is spread thinly across 33 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for urology clinicians in MS, where the typical reported total is $3,535.
Across 185 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$673
- Johnson & Johnson$608
- Bayer$584
- Pfizer$267
- Sumitomo Pharma America, Inc.$176
- Dendreon Pharmaceuticals LLC$167
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,31686%
- Education$52714%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 23 | $673 |
| Johnson & Johnson(2 entities) | 30 | $608 |
| Bayer | 36 | $584 |
| Pfizer | 16 | $267 |
| Sumitomo Pharma America, Inc. | 10 | $176 |
| Dendreon Pharmaceuticals LLC | 6 | $167 |
| Olympus America Inc. | 3 | $141 |
| AbbVie(2 entities) | 10 | $138 |
| Progenics Pharmaceuticals, Inc. | 6 | $134 |
| Endo Pharmaceuticals Inc. | 5 | $102 |
| Teleflex LLC | 3 | $85 |
| Merck | 4 | $79 |
| Intuitive Surgical | 1 | $77 |
| Coloplast | 3 | $71 |
| Procept Biorobotics Corporation | 3 | $67 |
| Novartis | 3 | $59 |
| Rochester Medical Corporation | 3 | $50 |
| Tolmar Pharmaceuticals, Inc. | 2 | $48 |
| Hollister Incorporated | 2 | $44 |
| Photocure Inc | 2 | $28 |
| Boehringer Ingelheim | 2 | $26 |
| ABC Home Medical Supply, Inc. | 1 | $26 |
| Myriad Genetic Laboratories, Inc. | 1 | $25 |
| Blue Earth Diagnostics | 1 | $24 |
| Tolmar, Inc. | 1 | $22 |
| Sagent Pharmaceuticals | 1 | $21 |
| Cycle Pharmaceuticals Inc | 1 | $18 |
| Boston Scientific | 1 | $16 |
| Axonics, Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $13 |
| Urogen Pharma, Inc. | 1 | $12 |
How this compares
$3,843 in reported general payments places this provider in the 50th percentile of 94 urology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 20 | $287,014 |
| MyrbetriqMirabegron | 51 | $51,512 |
| GemtesaVibegron | 31 | $26,867 |
| Tamsulosin Hcl | 1,158 | $21,318 |
| Finasteride | 667 | $10,466 |
| Methenamine Hippurate | 65 | $5,301 |
| Oxybutynin Chloride ErOxybutynin Chloride | 133 | $2,370 |
| Dutasteride | 73 | $2,255 |
| Estradiol | 29 | $2,170 |
| Bicalutamide | 73 | $1,930 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 60 | $1,709 |
| Potassium Citrate ErPotassium Citrate | 23 | $1,683 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 62 | $1,295 |
| Trospium Chloride | 13 | $1,052 |
| Oxybutynin Chloride | 70 | $856 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $673 | $338,52571 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $176 | $26,86731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 94 urology providers in Mississippi.
Other urology in Meridian
- Andrew GowdeyMeridian$5K
- Mark PhillipsMeridian$3K
- Sean DouglasHattiesburg$40K
- Robert HollabaughSouthaven$17K
- Kristopher WhiteheadTupelo$17K
- Harold BlalockJackson$15K
- Jon PoseyTupelo$13K
- Paul FarabaughTupelo$13K
- Clarance FarmerTupelo$12K
- Patrick DailyJackson$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.